Ultragenyx Pharmaceutical Inc
RARE31.035USD
-10.405-25.11%
Fechamento 07/10, 16:00（ET）Cotações atrasadas em 15 min
2.91BValor de mercado
PerdaP/L TTM
Mais detalhes de Ultragenyx Pharmaceutical Inc Empresa
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Informações da empresa
Código da empresaRARE
Nome da EmpresaUltragenyx Pharmaceutical Inc
Data de listagemJan 31, 2014
Fundado em2011
CEODr. Emil D. Kakkis, M.D., Ph.D.
Número de funcionários1294
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 31
Endereço60 Leveroni Ct
CidadeNOVATO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94949
Telefone14154838800
Sitehttps://www.ultragenyx.com/
Código da empresaRARE
Data de listagemJan 31, 2014
Fundado em2011
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
15.69K
-83.00%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Dr. Deborah L. Dunsire, M.D.
Dr. Deborah L. Dunsire, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Por RegiãoUSD
Nome
Receita
Proporção
North America
57.79M
41.49%
Latin America
54.89M
39.40%
Europe
23.33M
16.75%
Japan
3.29M
2.36%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
44.96%
Investment Advisor
27.79%
Hedge Fund
21.16%
Individual Investor
3.56%
Research Firm
1.72%
Sovereign Wealth Fund
1.02%
Private Equity
0.70%
Pension Fund
0.65%
Bank and Trust
0.28%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
627
96.81M
102.40%
-2.03M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
2023Q1
609
74.12M
105.56%
-2.85M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
9.98M
10.55%
-38.64K
-0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.91M
5.2%
-49.62K
-1.00%
Mar 31, 2025
Sands Capital Management, LLC
4.16M
4.4%
-134.44K
-3.13%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.14M
3.32%
+698.80K
+28.65%
Mar 31, 2025
Kakkis (Emil D)
2.69M
2.85%
-31.78K
-1.17%
Mar 07, 2025
State Street Global Advisors (US)
2.62M
2.77%
-104.13K
-3.82%
Mar 31, 2025
Wellington Management Company, LLP
2.45M
2.59%
-8.04K
-0.33%
Mar 31, 2025
ClearBridge Investments, LLC
2.26M
2.39%
-62.50K
-2.69%
Mar 31, 2025
Adage Capital Management, L.P.
2.15M
2.27%
+965.92K
+81.64%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
2.05M
2.17%
+3.00K
+0.15%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Global X Genomics & Biotechnology ETF
3.89%
Motley Fool Small-Cap Growth ETF
3%
Motley Fool Mid-Cap Growth ETF
2.01%
Franklin Genomic Advancements ETF
2%
Virtus LifeSci Biotech Products ETF
1.84%
Touchstone Sands Capital US Select Growth ETF
1.26%
WisdomTree BioRevolution Fund
1.12%
SPDR S&P Biotech ETF
0.77%
Putnam Sustainable Future ETF
0.63%
Goldman Sachs Future Health Care Equity ETF
0.6%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção3.89%
Motley Fool Small-Cap Growth ETF
Proporção3%
Motley Fool Mid-Cap Growth ETF
Proporção2.01%
Franklin Genomic Advancements ETF
Proporção2%
Virtus LifeSci Biotech Products ETF
Proporção1.84%
Touchstone Sands Capital US Select Growth ETF
Proporção1.26%
WisdomTree BioRevolution Fund
Proporção1.12%
SPDR S&P Biotech ETF
Proporção0.77%
Putnam Sustainable Future ETF
Proporção0.63%
Goldman Sachs Future Health Care Equity ETF
Proporção0.6%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
